COMydAL Program

Friday, October 6, 2023
09:15-10:45 Session 1: Classification, risk stratification & response assessment updates for MDS
Moderator: Ana Alfonso Piérola, Spain
09:15-09:30 Prognostication updates: Matteo Della Porta, Italy
09:30-09:45 Classification updates: Leonor Arenillas, Spain
09:45-10:00 Response assessment updates: Amer Zeidan, USA
10:00-10:15 Is MRD assessment ready for use in MDS? Arjan van de Loosdrecht, Netherlands
10:15-10:45 Roundtable discussion: All session faculty
10:45-11:15 Coffee Break
11:15-12:45 Session 2: Management of lower risk MDS
Moderator: David Valcárcel, Spain
11:15-11:30 ESA/Lenalidomide/IST/chelation: María Díez Campelo, Spain
11:30-11:45 What is the role for chelation in MDS? TBA
11:45-12:00 Imetelstat/TGF-beta/Roxadustat: Valeria Santini, Italy
12:00-12:15 Early phase agent review: Rami Komrokji, USA
12:15-12:45 Roundtable discussion: All session faculty
12:45-13:00 Lunch Box pick-up and Break
13:00-14:30 Special IACH CME Session over lunch
14:30-14:45 Technical Break
14:45-16:15 Session 3: Management of higher risk MDS
Moderator: Marie Sébert, France
14:45-15:00 Injectable and oral HMAs: Pierre Fenaux, France
15:00-15:15 Novel agents in advanced trials (Magro/Sabato): Guillermo Sanz, Spain
15:15-15:30 IDH inhibitors for MDS: Lionel Ades, France
15:30-15:45 Early phase agent review: TBA
15:45:16:15 Roundtable discussion: All session faculty
16:15-16:45 Coffee Break
16:45-18:15 Session 4: Prognosis, MRD and transplantation for AML
Moderator: Agnieszka Wierzbowska, Poland
16:45-17:00 Risk stratification in AML: TBA
17:00-17:15 What is the role of MRD in AML? Gert Ossenkoppele, Netherlands
17:15-17:30 How should we manage patients with MDS/AML? Raphael Itzykson, France
17:30-17:45 Should we use maintenance therapy post-transplant? TBA
17:45-18:15 Roundtable discussion: All session faculty
Saturday, October 7, 2023
09:15-10:45 Session 5: Updates in AML management in 2023 – Agents in clinic
Moderator: Andrew Wei, Australia
09:15-09:30 What is standard frontline therapy for fit patients in 2023? Jessica Altman, USA
09:30-09:45 What is standard frontline therapy for unfit patients in 2023? Amer Zeidan, USA
09:45-10:00 How do I manage relapsed/refractory AML in 2023? Andrew Wei, Australia
10:00-10:15 Do triplets have a place in current practice of AML? Gail Roboz, USA
10:15-10:45 Roundtable discussion: All session faculty
10:45-11:15 Coffee Break
11:15-12:45 Session 6: Updates in AML management in 2023 – Investigational approaches
Moderator: Marion Subklewe, Germany
11:15-11:30 Which agents in development have the most promise? Thomas Cluzeau, France
11:30-11:45 Immune investigational approaches (ADCs, Bites, CAR T cells, ICB): Marion Subklewe, Germany
11:45-12:00 Options for patients with TP53 mutant MDS/AML? Naval Daver, USA
12:00-12:15 Updates in mechanisms of resistance in AML and how to overcome them: Klaus Metzeler, Germany
12:15-12:45 Roundtable discussion: All session faculty
12:45-13:00 Lunch Box pick-up and Break
13:00-14:30 Industry-supported Lunch Symposium
14:30-14:45 Technical Break
14:45-16:15 Session 7: How do I manage ALL in 2o23?
Moderator: TBA
14:45-15:00 Ph -ve ALL: Robin Foà, Italy
15:00-15:15 Ph +ve ALL: Elias Jabbour, USA
15:15-15:30 T-cell ALL: TBA
15:30-15:45 Cellular therapy and transplant considerations for ALL: Sridhar Chaganti, UK
15:45:16:15 Roundtable discussion: All session faculty